logo
ResearchBunny Logo
Rapid neuroplasticity changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression

Medicine and Health

Rapid neuroplasticity changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression

J. Kopelman, T. A. Keller, et al.

This groundbreaking study by Jared Kopelman and colleagues uncovers how rapid neuroplasticity changes may influence the response to intravenous ketamine in adults with treatment-resistant depression. Discover how ketamine's transformative effects are linked to gray matter microstructural alterations and what this means for future treatments.

00:00
00:00
~3 min • Beginner • English
Abstract
Intravenous ketamine is posed to rapidly reverse depression by rapidly enhancing neuroplasticity. In human patients, we quantified gray matter microstructural changes on a rapid (24-h) timescale within key regions where neuroplasticity enhancements post-ketamine have been implicated in animal models. In this study, 98 unipolar depressed adults who failed at least one antidepressant medication were randomized 2:1 to a single infusion of intravenous ketamine (0.5 mg/kg) or vehicle (saline) and completed diffusion tensor imaging (DTI) assessments at pre-infusion baseline and 24-h post-infusion. DTI mean diffusivity (DTI-MD), a putative marker of microstructural neuroplasticity in gray matter, was calculated for 7 regions of interest (left and right BA10, amygdala, and hippocampus; and ventral Anterior Cingulate Cortex) and compared to clinical response measured with the Montgomery-Asberg Depression Rating Scale (MADRS) and the Quick Inventory of Depressive Symptoms-Self-Report (QIDS-SR). Individual differences in DTI-MD change (greater decrease from baseline to 24-h post-infusion, indicative of more neuroplasticity enhancement) were associated with larger improvements in depression scores across several regions. In the left BA10 and left amygdala, these relationships were driven primarily by the ketamine group (group * DTI-MD interaction effects: p = 0.016–0.082). In the right BA10, these associations expanded to both infusions (p = 0.007). In the left and right hippocampus, on the MADRS only, interaction effects were observed in the opposite direction, such that DTI-MD change was inversely associated with depression change in the ketamine group (group * DTI-MD interaction effects: p = 0.032–0.06). The active effects of ketamine on depression may be mediated, in part, by acute changes in neuroplasticity quantified with DTI.
Publisher
Translational Psychiatry
Published On
Authors
Jared Kopelman, Timothy A. Keller, Benjamin Panny, Angela Griffo, Michelle Degutis, Crystal Spott, Nicolas Cruz, Elizabeth Bell, Kevin Do-Young, Meredith L. Wallace, Sanjay J. Mathew, Robert H. Howland, Rebecca B. Price
Tags
ketamine
neuroplasticity
treatment-resistant depression
gray matter
diffusion tensor imaging
clinical trial
Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny